Travere Therapeutics (TVTX) Set to Announce Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) will be announcing its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). The company had revenue of $54.12 million during the quarter, compared to the consensus estimate of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Down 0.1 %

Shares of NASDAQ TVTX opened at $17.96 on Thursday. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $19.25. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. The firm has a market cap of $1.37 billion, a PE ratio of -8.55 and a beta of 0.73. The company’s fifty day simple moving average is $13.08 and its 200 day simple moving average is $9.51.

Insiders Place Their Bets

In other news, Director Gary A. Lyons sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $14.73, for a total value of $589,200.00. Following the completion of the transaction, the director now directly owns 51,000 shares of the company’s stock, valued at $751,230. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary A. Lyons sold 40,000 shares of the stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $14.73, for a total transaction of $589,200.00. Following the transaction, the director now directly owns 51,000 shares of the company’s stock, valued at $751,230. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,707 shares of company stock valued at $1,504,312 in the last 90 days. 3.75% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TVTX. HC Wainwright decreased their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Guggenheim upped their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Scotiabank assumed coverage on shares of Travere Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $23.00 price objective on the stock. Leerink Partners reissued an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $9.00 to $27.00 in a research report on Monday. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.38.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.